EOM Pharmaceutical (OTCMKTS:IMUC) and Akebia Therapeutics (NASDAQ:AKBA) Head to Head Survey

Akebia Therapeutics (NASDAQ:AKBA) and EOM Pharmaceutical (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Volatility and Risk

Akebia Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, EOM Pharmaceutical has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Valuation and Earnings

This table compares Akebia Therapeutics and EOM Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$160.18 million	2.50	-$69.41 million	($0.07)	-21.57
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A

EOM Pharmaceutical has lower revenue, but higher earnings than Akebia Therapeutics.

Analyst Ratings

This is a summary of recent ratings for Akebia Therapeutics and EOM Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1	1	4	1	2.71
EOM Pharmaceutical	0	0	0	0	0.00

Akebia Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 297.35%. Given Akebia Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than EOM Pharmaceutical.

Insider & Institutional Ownership

33.9% of Akebia Therapeutics shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by company insiders. Comparatively, 3.3% of EOM Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Akebia Therapeutics and EOM Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-7.07%	-137.67%	-5.13%
EOM Pharmaceutical	N/A	N/A	N/A

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.